Biotechnology company Creative Medical Technology Holdings, Inc. (CELZ) announced Tuesday that it has received Institutional Review Board (IRB) approval to proceed with its clinical trial for the treatment of chronic lower back pain with its StemSpine procedure using AlloStem (CELZ-201-DDT) cell therapy.
Creative Medical Technology Holdings got FDA clearance for its Phase 1/2 clinical trial for its StemSpine procedure using AlloStem, according to a Sept. 19 news release.